nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—ADRA1B—vas deferens—urinary bladder cancer	0.286	0.76	CbGeAlD
Lisdexamfetamine—SLC18A2—prostate gland—urinary bladder cancer	0.0253	0.0672	CbGeAlD
Lisdexamfetamine—Aspartame—TRPV1—urinary bladder cancer	0.0183	1	CrCbGaD
Lisdexamfetamine—ADRA1B—renal system—urinary bladder cancer	0.0174	0.0462	CbGeAlD
Lisdexamfetamine—SLC18A2—female reproductive system—urinary bladder cancer	0.0138	0.0367	CbGeAlD
Lisdexamfetamine—SLC18A2—vagina—urinary bladder cancer	0.0125	0.0332	CbGeAlD
Lisdexamfetamine—SLC6A2—female reproductive system—urinary bladder cancer	0.00842	0.0224	CbGeAlD
Lisdexamfetamine—SLC18A2—lymph node—urinary bladder cancer	0.00808	0.0215	CbGeAlD
Lisdexamfetamine—SLC6A2—lymph node—urinary bladder cancer	0.00493	0.0131	CbGeAlD
Lisdexamfetamine—Hypertension—Gemcitabine—urinary bladder cancer	0.00194	0.0032	CcSEcCtD
Lisdexamfetamine—Somnolence—Thiotepa—urinary bladder cancer	0.00194	0.0032	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Thiotepa—urinary bladder cancer	0.00192	0.00317	CcSEcCtD
Lisdexamfetamine—Convulsion—Fluorouracil—urinary bladder cancer	0.00191	0.00316	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.0019	0.00313	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Thiotepa—urinary bladder cancer	0.00189	0.00313	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00188	0.0031	CcSEcCtD
Lisdexamfetamine—Fatigue—Thiotepa—urinary bladder cancer	0.00188	0.0031	CcSEcCtD
Lisdexamfetamine—Constipation—Thiotepa—urinary bladder cancer	0.00186	0.00308	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00183	0.00303	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Epirubicin—urinary bladder cancer	0.00182	0.00301	CcSEcCtD
Lisdexamfetamine—Irritability—Methotrexate—urinary bladder cancer	0.00182	0.003	CcSEcCtD
Lisdexamfetamine—Convulsion—Cisplatin—urinary bladder cancer	0.00181	0.00299	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.0018	0.00297	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.0018	0.00297	CcSEcCtD
Lisdexamfetamine—Diplopia—Epirubicin—urinary bladder cancer	0.00178	0.00295	CcSEcCtD
Lisdexamfetamine—Skin disorder—Gemcitabine—urinary bladder cancer	0.00178	0.00294	CcSEcCtD
Lisdexamfetamine—Anxiety—Cisplatin—urinary bladder cancer	0.00177	0.00293	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.00177	0.00292	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00177	0.00292	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00177	0.00292	CcSEcCtD
Lisdexamfetamine—Tachycardia—Fluorouracil—urinary bladder cancer	0.00176	0.0029	CcSEcCtD
Lisdexamfetamine—Affect lability—Epirubicin—urinary bladder cancer	0.00176	0.0029	CcSEcCtD
Lisdexamfetamine—Anorexia—Gemcitabine—urinary bladder cancer	0.00175	0.00288	CcSEcCtD
Lisdexamfetamine—Urticaria—Thiotepa—urinary bladder cancer	0.00173	0.00286	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Thiotepa—urinary bladder cancer	0.00172	0.00284	CcSEcCtD
Lisdexamfetamine—Anorexia—Fluorouracil—urinary bladder cancer	0.00172	0.00284	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.00172	0.00284	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00171	0.00282	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Doxorubicin—urinary bladder cancer	0.00168	0.00278	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00167	0.00277	CcSEcCtD
Lisdexamfetamine—Tachycardia—Cisplatin—urinary bladder cancer	0.00167	0.00275	CcSEcCtD
Lisdexamfetamine—Convulsion—Etoposide—urinary bladder cancer	0.00166	0.00274	CcSEcCtD
Lisdexamfetamine—Skin disorder—Cisplatin—urinary bladder cancer	0.00166	0.00274	CcSEcCtD
Lisdexamfetamine—Insomnia—Gemcitabine—urinary bladder cancer	0.00166	0.00274	CcSEcCtD
Lisdexamfetamine—Hypertension—Etoposide—urinary bladder cancer	0.00165	0.00273	CcSEcCtD
Lisdexamfetamine—Diplopia—Doxorubicin—urinary bladder cancer	0.00165	0.00273	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.00165	0.00273	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00163	0.0027	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.00163	0.00269	CcSEcCtD
Lisdexamfetamine—Insomnia—Fluorouracil—urinary bladder cancer	0.00163	0.00269	CcSEcCtD
Lisdexamfetamine—Somnolence—Gemcitabine—urinary bladder cancer	0.00163	0.00269	CcSEcCtD
Lisdexamfetamine—Anorexia—Cisplatin—urinary bladder cancer	0.00163	0.00269	CcSEcCtD
Lisdexamfetamine—Affect lability—Doxorubicin—urinary bladder cancer	0.00162	0.00268	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00162	0.00268	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.00161	0.00265	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00161	0.00265	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.0016	0.00265	CcSEcCtD
Lisdexamfetamine—Somnolence—Fluorouracil—urinary bladder cancer	0.0016	0.00264	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Gemcitabine—urinary bladder cancer	0.00159	0.00263	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00158	0.00262	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00158	0.00261	CcSEcCtD
Lisdexamfetamine—Fatigue—Gemcitabine—urinary bladder cancer	0.00158	0.00261	CcSEcCtD
Lisdexamfetamine—Constipation—Gemcitabine—urinary bladder cancer	0.00157	0.00259	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00157	0.00259	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00156	0.00258	CcSEcCtD
Lisdexamfetamine—Asthenia—Thiotepa—urinary bladder cancer	0.00156	0.00258	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00155	0.00257	CcSEcCtD
Lisdexamfetamine—Tachycardia—Etoposide—urinary bladder cancer	0.00153	0.00252	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Cisplatin—urinary bladder cancer	0.00152	0.00251	CcSEcCtD
Lisdexamfetamine—Skin disorder—Etoposide—urinary bladder cancer	0.00152	0.00251	CcSEcCtD
Lisdexamfetamine—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.00152	0.00251	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Etoposide—urinary bladder cancer	0.00151	0.0025	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.00151	0.00249	CcSEcCtD
Lisdexamfetamine—Anorexia—Etoposide—urinary bladder cancer	0.00149	0.00246	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Thiotepa—urinary bladder cancer	0.00149	0.00246	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.00149	0.00245	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Cisplatin—urinary bladder cancer	0.00148	0.00245	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00147	0.00243	CcSEcCtD
Lisdexamfetamine—Depression—Methotrexate—urinary bladder cancer	0.00146	0.00242	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.00146	0.00241	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00145	0.00239	CcSEcCtD
Lisdexamfetamine—Dizziness—Thiotepa—urinary bladder cancer	0.00144	0.00238	CcSEcCtD
Lisdexamfetamine—Urticaria—Fluorouracil—urinary bladder cancer	0.00143	0.00236	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.00142	0.00235	CcSEcCtD
Lisdexamfetamine—Weight increased—Epirubicin—urinary bladder cancer	0.0014	0.00232	CcSEcCtD
Lisdexamfetamine—Weight decreased—Epirubicin—urinary bladder cancer	0.00139	0.0023	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Etoposide—urinary bladder cancer	0.00139	0.0023	CcSEcCtD
Lisdexamfetamine—Somnolence—Etoposide—urinary bladder cancer	0.00139	0.0023	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.00139	0.00229	CcSEcCtD
Lisdexamfetamine—Vomiting—Thiotepa—urinary bladder cancer	0.00138	0.00229	CcSEcCtD
Lisdexamfetamine—Rash—Thiotepa—urinary bladder cancer	0.00137	0.00227	CcSEcCtD
Lisdexamfetamine—Dermatitis—Thiotepa—urinary bladder cancer	0.00137	0.00227	CcSEcCtD
Lisdexamfetamine—Headache—Thiotepa—urinary bladder cancer	0.00136	0.00225	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.00136	0.00225	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Etoposide—urinary bladder cancer	0.00136	0.00225	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00135	0.00223	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Cisplatin—urinary bladder cancer	0.00135	0.00223	CcSEcCtD
Lisdexamfetamine—Fatigue—Etoposide—urinary bladder cancer	0.00135	0.00223	CcSEcCtD
Lisdexamfetamine—Constipation—Etoposide—urinary bladder cancer	0.00134	0.00221	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00133	0.00219	CcSEcCtD
Lisdexamfetamine—Hepatitis—Methotrexate—urinary bladder cancer	0.00132	0.00218	CcSEcCtD
Lisdexamfetamine—Asthenia—Gemcitabine—urinary bladder cancer	0.00131	0.00217	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.0013	0.00215	CcSEcCtD
Lisdexamfetamine—Weight increased—Doxorubicin—urinary bladder cancer	0.0013	0.00214	CcSEcCtD
Lisdexamfetamine—Nausea—Thiotepa—urinary bladder cancer	0.00129	0.00214	CcSEcCtD
Lisdexamfetamine—Weight decreased—Doxorubicin—urinary bladder cancer	0.00129	0.00213	CcSEcCtD
Lisdexamfetamine—Visual impairment—Methotrexate—urinary bladder cancer	0.00127	0.0021	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.00126	0.00208	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00126	0.00208	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00125	0.00207	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Methotrexate—urinary bladder cancer	0.00125	0.00206	CcSEcCtD
Lisdexamfetamine—Urticaria—Etoposide—urinary bladder cancer	0.00124	0.00205	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Etoposide—urinary bladder cancer	0.00124	0.00204	CcSEcCtD
Lisdexamfetamine—Hepatitis—Epirubicin—urinary bladder cancer	0.00123	0.00204	CcSEcCtD
Lisdexamfetamine—Eye disorder—Methotrexate—urinary bladder cancer	0.00123	0.00204	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00123	0.00204	CcSEcCtD
Lisdexamfetamine—Asthenia—Cisplatin—urinary bladder cancer	0.00122	0.00202	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Methotrexate—urinary bladder cancer	0.00122	0.00202	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.0012	0.00199	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Methotrexate—urinary bladder cancer	0.00119	0.00197	CcSEcCtD
Lisdexamfetamine—Dizziness—Fluorouracil—urinary bladder cancer	0.00119	0.00197	CcSEcCtD
Lisdexamfetamine—Visual impairment—Epirubicin—urinary bladder cancer	0.00119	0.00196	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.00119	0.00196	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Cisplatin—urinary bladder cancer	0.00117	0.00193	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Epirubicin—urinary bladder cancer	0.00117	0.00193	CcSEcCtD
Lisdexamfetamine—Vomiting—Gemcitabine—urinary bladder cancer	0.00116	0.00192	CcSEcCtD
Lisdexamfetamine—Mental disorder—Methotrexate—urinary bladder cancer	0.00115	0.00191	CcSEcCtD
Lisdexamfetamine—Rash—Gemcitabine—urinary bladder cancer	0.00115	0.00191	CcSEcCtD
Lisdexamfetamine—Dermatitis—Gemcitabine—urinary bladder cancer	0.00115	0.00191	CcSEcCtD
Lisdexamfetamine—Eye disorder—Epirubicin—urinary bladder cancer	0.00115	0.0019	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Etoposide—urinary bladder cancer	0.00115	0.0019	CcSEcCtD
Lisdexamfetamine—Malnutrition—Methotrexate—urinary bladder cancer	0.00115	0.0019	CcSEcCtD
Lisdexamfetamine—Headache—Gemcitabine—urinary bladder cancer	0.00115	0.0019	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Epirubicin—urinary bladder cancer	0.00114	0.00189	CcSEcCtD
Lisdexamfetamine—Vomiting—Fluorouracil—urinary bladder cancer	0.00114	0.00189	CcSEcCtD
Lisdexamfetamine—Hepatitis—Doxorubicin—urinary bladder cancer	0.00114	0.00189	CcSEcCtD
Lisdexamfetamine—Rash—Fluorouracil—urinary bladder cancer	0.00114	0.00188	CcSEcCtD
Lisdexamfetamine—Dermatitis—Fluorouracil—urinary bladder cancer	0.00113	0.00187	CcSEcCtD
Lisdexamfetamine—Headache—Fluorouracil—urinary bladder cancer	0.00113	0.00186	CcSEcCtD
Lisdexamfetamine—Asthenia—Etoposide—urinary bladder cancer	0.00112	0.00185	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Epirubicin—urinary bladder cancer	0.00111	0.00184	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.00111	0.00184	CcSEcCtD
Lisdexamfetamine—Visual impairment—Doxorubicin—urinary bladder cancer	0.0011	0.00182	CcSEcCtD
Lisdexamfetamine—Nausea—Gemcitabine—urinary bladder cancer	0.00109	0.0018	CcSEcCtD
Lisdexamfetamine—Vomiting—Cisplatin—urinary bladder cancer	0.00109	0.00179	CcSEcCtD
Lisdexamfetamine—Vision blurred—Methotrexate—urinary bladder cancer	0.00108	0.00179	CcSEcCtD
Lisdexamfetamine—Mental disorder—Epirubicin—urinary bladder cancer	0.00108	0.00179	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.00108	0.00178	CcSEcCtD
Lisdexamfetamine—Rash—Cisplatin—urinary bladder cancer	0.00108	0.00178	CcSEcCtD
Lisdexamfetamine—Dermatitis—Cisplatin—urinary bladder cancer	0.00108	0.00178	CcSEcCtD
Lisdexamfetamine—Malnutrition—Epirubicin—urinary bladder cancer	0.00107	0.00177	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Etoposide—urinary bladder cancer	0.00107	0.00177	CcSEcCtD
Lisdexamfetamine—Nausea—Fluorouracil—urinary bladder cancer	0.00107	0.00177	CcSEcCtD
Lisdexamfetamine—Eye disorder—Doxorubicin—urinary bladder cancer	0.00107	0.00176	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.00106	0.00175	CcSEcCtD
Lisdexamfetamine—Nervousness—Epirubicin—urinary bladder cancer	0.00104	0.00172	CcSEcCtD
Lisdexamfetamine—Dizziness—Etoposide—urinary bladder cancer	0.00103	0.00171	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Doxorubicin—urinary bladder cancer	0.00103	0.0017	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.00103	0.0017	CcSEcCtD
Lisdexamfetamine—Nausea—Cisplatin—urinary bladder cancer	0.00101	0.00167	CcSEcCtD
Lisdexamfetamine—Vision blurred—Epirubicin—urinary bladder cancer	0.00101	0.00167	CcSEcCtD
Lisdexamfetamine—Mental disorder—Doxorubicin—urinary bladder cancer	0.001	0.00165	CcSEcCtD
Lisdexamfetamine—Convulsion—Methotrexate—urinary bladder cancer	0.000994	0.00164	CcSEcCtD
Lisdexamfetamine—Vomiting—Etoposide—urinary bladder cancer	0.000994	0.00164	CcSEcCtD
Lisdexamfetamine—Malnutrition—Doxorubicin—urinary bladder cancer	0.000994	0.00164	CcSEcCtD
Lisdexamfetamine—Agitation—Epirubicin—urinary bladder cancer	0.000987	0.00163	CcSEcCtD
Lisdexamfetamine—Rash—Etoposide—urinary bladder cancer	0.000986	0.00163	CcSEcCtD
Lisdexamfetamine—Dermatitis—Etoposide—urinary bladder cancer	0.000985	0.00163	CcSEcCtD
Lisdexamfetamine—Headache—Etoposide—urinary bladder cancer	0.00098	0.00162	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.00097	0.0016	CcSEcCtD
Lisdexamfetamine—Nervousness—Doxorubicin—urinary bladder cancer	0.000965	0.00159	CcSEcCtD
Lisdexamfetamine—Palpitations—Epirubicin—urinary bladder cancer	0.000949	0.00157	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000937	0.00155	CcSEcCtD
Lisdexamfetamine—Vision blurred—Doxorubicin—urinary bladder cancer	0.000936	0.00155	CcSEcCtD
Lisdexamfetamine—Convulsion—Epirubicin—urinary bladder cancer	0.00093	0.00154	CcSEcCtD
Lisdexamfetamine—Nausea—Etoposide—urinary bladder cancer	0.000929	0.00153	CcSEcCtD
Lisdexamfetamine—Hypertension—Epirubicin—urinary bladder cancer	0.000927	0.00153	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000918	0.00152	CcSEcCtD
Lisdexamfetamine—Agitation—Doxorubicin—urinary bladder cancer	0.000913	0.00151	CcSEcCtD
Lisdexamfetamine—Anxiety—Epirubicin—urinary bladder cancer	0.000911	0.00151	CcSEcCtD
Lisdexamfetamine—Skin disorder—Methotrexate—urinary bladder cancer	0.00091	0.0015	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000908	0.0015	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000905	0.0015	CcSEcCtD
Lisdexamfetamine—Dry mouth—Epirubicin—urinary bladder cancer	0.000894	0.00148	CcSEcCtD
Lisdexamfetamine—Anorexia—Methotrexate—urinary bladder cancer	0.000893	0.00147	CcSEcCtD
Lisdexamfetamine—Palpitations—Doxorubicin—urinary bladder cancer	0.000878	0.00145	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000876	0.00145	CcSEcCtD
Lisdexamfetamine—Convulsion—Doxorubicin—urinary bladder cancer	0.000861	0.00142	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.00086	0.00142	CcSEcCtD
Lisdexamfetamine—Hypertension—Doxorubicin—urinary bladder cancer	0.000858	0.00142	CcSEcCtD
Lisdexamfetamine—Tachycardia—Epirubicin—urinary bladder cancer	0.000855	0.00141	CcSEcCtD
Lisdexamfetamine—Skin disorder—Epirubicin—urinary bladder cancer	0.000851	0.00141	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000847	0.0014	CcSEcCtD
Lisdexamfetamine—Insomnia—Methotrexate—urinary bladder cancer	0.000847	0.0014	CcSEcCtD
Lisdexamfetamine—Anxiety—Doxorubicin—urinary bladder cancer	0.000843	0.00139	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.00084	0.00139	CcSEcCtD
Lisdexamfetamine—Anorexia—Epirubicin—urinary bladder cancer	0.000835	0.00138	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Methotrexate—urinary bladder cancer	0.000835	0.00138	CcSEcCtD
Lisdexamfetamine—Somnolence—Methotrexate—urinary bladder cancer	0.000833	0.00138	CcSEcCtD
Lisdexamfetamine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000827	0.00137	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000824	0.00136	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000814	0.00135	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000811	0.00134	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000809	0.00134	CcSEcCtD
Lisdexamfetamine—Fatigue—Methotrexate—urinary bladder cancer	0.000807	0.00133	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000795	0.00131	CcSEcCtD
Lisdexamfetamine—Insomnia—Epirubicin—urinary bladder cancer	0.000793	0.00131	CcSEcCtD
Lisdexamfetamine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000791	0.00131	CcSEcCtD
Lisdexamfetamine—Skin disorder—Doxorubicin—urinary bladder cancer	0.000788	0.0013	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000784	0.0013	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Epirubicin—urinary bladder cancer	0.000781	0.00129	CcSEcCtD
Lisdexamfetamine—Somnolence—Epirubicin—urinary bladder cancer	0.000779	0.00129	CcSEcCtD
Lisdexamfetamine—Anorexia—Doxorubicin—urinary bladder cancer	0.000773	0.00128	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000772	0.00127	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000762	0.00126	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000757	0.00125	CcSEcCtD
Lisdexamfetamine—Fatigue—Epirubicin—urinary bladder cancer	0.000756	0.00125	CcSEcCtD
Lisdexamfetamine—Constipation—Epirubicin—urinary bladder cancer	0.000749	0.00124	CcSEcCtD
Lisdexamfetamine—Urticaria—Methotrexate—urinary bladder cancer	0.000744	0.00123	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Methotrexate—urinary bladder cancer	0.00074	0.00122	CcSEcCtD
Lisdexamfetamine—Insomnia—Doxorubicin—urinary bladder cancer	0.000733	0.00121	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000723	0.00119	CcSEcCtD
Lisdexamfetamine—Somnolence—Doxorubicin—urinary bladder cancer	0.000721	0.00119	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000714	0.00118	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000705	0.00116	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.0007	0.00116	CcSEcCtD
Lisdexamfetamine—Fatigue—Doxorubicin—urinary bladder cancer	0.000699	0.00116	CcSEcCtD
Lisdexamfetamine—Urticaria—Epirubicin—urinary bladder cancer	0.000696	0.00115	CcSEcCtD
Lisdexamfetamine—Constipation—Doxorubicin—urinary bladder cancer	0.000693	0.00115	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000693	0.00114	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.00069	0.00114	CcSEcCtD
Lisdexamfetamine—Asthenia—Methotrexate—urinary bladder cancer	0.000672	0.00111	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000646	0.00107	CcSEcCtD
Lisdexamfetamine—Urticaria—Doxorubicin—urinary bladder cancer	0.000644	0.00106	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000641	0.00106	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000641	0.00106	CcSEcCtD
Lisdexamfetamine—Asthenia—Epirubicin—urinary bladder cancer	0.000629	0.00104	CcSEcCtD
Lisdexamfetamine—Dizziness—Methotrexate—urinary bladder cancer	0.000619	0.00102	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Epirubicin—urinary bladder cancer	0.0006	0.000991	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000597	0.000987	CcSEcCtD
Lisdexamfetamine—Vomiting—Methotrexate—urinary bladder cancer	0.000595	0.000984	CcSEcCtD
Lisdexamfetamine—Rash—Methotrexate—urinary bladder cancer	0.000591	0.000976	CcSEcCtD
Lisdexamfetamine—Dermatitis—Methotrexate—urinary bladder cancer	0.00059	0.000975	CcSEcCtD
Lisdexamfetamine—Headache—Methotrexate—urinary bladder cancer	0.000587	0.000969	CcSEcCtD
Lisdexamfetamine—Asthenia—Doxorubicin—urinary bladder cancer	0.000582	0.000961	CcSEcCtD
Lisdexamfetamine—Dizziness—Epirubicin—urinary bladder cancer	0.00058	0.000958	CcSEcCtD
Lisdexamfetamine—Vomiting—Epirubicin—urinary bladder cancer	0.000557	0.000921	CcSEcCtD
Lisdexamfetamine—Nausea—Methotrexate—urinary bladder cancer	0.000556	0.000919	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000555	0.000917	CcSEcCtD
Lisdexamfetamine—Rash—Epirubicin—urinary bladder cancer	0.000553	0.000913	CcSEcCtD
Lisdexamfetamine—Dermatitis—Epirubicin—urinary bladder cancer	0.000552	0.000912	CcSEcCtD
Lisdexamfetamine—Headache—Epirubicin—urinary bladder cancer	0.000549	0.000907	CcSEcCtD
Lisdexamfetamine—Dizziness—Doxorubicin—urinary bladder cancer	0.000536	0.000886	CcSEcCtD
Lisdexamfetamine—Nausea—Epirubicin—urinary bladder cancer	0.000521	0.00086	CcSEcCtD
Lisdexamfetamine—Vomiting—Doxorubicin—urinary bladder cancer	0.000516	0.000852	CcSEcCtD
Lisdexamfetamine—Rash—Doxorubicin—urinary bladder cancer	0.000511	0.000845	CcSEcCtD
Lisdexamfetamine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000511	0.000844	CcSEcCtD
Lisdexamfetamine—Headache—Doxorubicin—urinary bladder cancer	0.000508	0.000839	CcSEcCtD
Lisdexamfetamine—Nausea—Doxorubicin—urinary bladder cancer	0.000482	0.000796	CcSEcCtD
